A recent study conducted on HCC patients, of which 10 patients received anti-PD-1 therapy (9 with nivolumab and 1 with pembrolizumab), reported that all patients (n = 4) who did not have PD-L1+CTCs were non-responders (patients with PD or died within 6 months from initiating treatment). Here, CD274 is linked to hepatocellular carcinoma.